Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Andexxa—An Antidote for Apixaban and Rivaroxaban

Andexxa—An Antidote for Apixaban and Rivaroxaban This Medical Letter review discusses the mechanism of action, adverse effects, and cost associated with coagulation factor Xa that was approved by the US Food and Drug Administration for reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban and rivaroxaban. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Andexxa—An Antidote for Apixaban and Rivaroxaban

JAMA , Volume 320 (4) – Jul 24, 2018

Loading next page...
 
/lp/american-medical-association/andexxa-an-antidote-for-apixaban-and-rivaroxaban-WxWmTSFbSA
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2018.9257
Publisher site
See Article on Publisher Site

Abstract

This Medical Letter review discusses the mechanism of action, adverse effects, and cost associated with coagulation factor Xa that was approved by the US Food and Drug Administration for reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban and rivaroxaban.

Journal

JAMAAmerican Medical Association

Published: Jul 24, 2018

References